Effects of Vitamin D Insufficiency in Man
Primary Purpose
Vitamin D Deficiency
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Vitamin D2
Vitamin D3
Sponsored by
About this trial
This is an interventional treatment trial for Vitamin D Deficiency
Eligibility Criteria
Inclusion Criteria:
- 25D levels <30 ng/ml (Vitamin D sufficient) OR <20 ng/ml (Vitamin D deficient)
- At least 18 years of age
Exclusion Criteria:
- Hypercalcemia
- Hyperparathyroidism
- Hyperthyroidism
- Hypercalciuria
- Renal disease
- Intestinal malabsorption any disorder that places the subject at risk for developing hypercalcemia or hypercalciuria during standard vitamin D replacement therapy owing to the presence of underlying dysregulated vitamin D metabolism (e.g., sarcoidosis, TB, etc)
Sites / Locations
- UCLA
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Vitamin D2
Vitamin D3
Arm Description
Total of 500,000 IU vitamin D2 (50,000 IU twice weekly for 5 weeks)
Total of 500,000 IU vitamin D3 (50,000 IU twice weekly for 5 weeks)
Outcomes
Primary Outcome Measures
Change in serum 25D
Secondary Outcome Measures
Change in bone mineral density by biochemistry
Change in muscle strength by exam
Change in muscle strength by questionnaire
Change in bone mineral density by DXA scan
Change in fractional urinary calcium:creatinine excretion ratio
Change in serum 1,25D
Change in serum iPTH
Change in serum bone biomarkers
Full Information
NCT ID
NCT01848236
First Posted
May 2, 2013
Last Updated
February 28, 2020
Sponsor
University of California, Los Angeles
1. Study Identification
Unique Protocol Identification Number
NCT01848236
Brief Title
Effects of Vitamin D Insufficiency in Man
Official Title
Effects of Vitamin D Insufficiency in Man
Study Type
Interventional
2. Study Status
Record Verification Date
February 2020
Overall Recruitment Status
Completed
Study Start Date
August 2010 (Actual)
Primary Completion Date
February 2020 (Actual)
Study Completion Date
February 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Los Angeles
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
We would like to determine if vitamin D insufficiency exists in different ethnic groups, if it has an effect on bone mass and muscle function, if it has an impact on the function of the cells of the immune system, and if the functioning level of these systems can be improved by stabilizing the vitamin D levels to within normal limits.
Detailed Description
Vitamin D is a hormone that can either be made in the skin under the influence of sunlight or absorbed from the diet. Roughly 50% of the U.S. population suffers from an insufficiency of vitamin D and its more active metabolites. This defect can result in disorders in the bones, muscles and immune system. In humans, these disorders usually present themselves as decreased bone mass, decreased muscle strength and increased susceptibility to some infections, respectively.
Therefore, the purpose of this study is to:
determine, by use of skeletal and immune biomarkers in the blood and urine, whether vitamin D insufficiency exists in differently pigmented ethnic groups; skin pigmentation blocks vitamin D production in the skin;
determine whether the vitamin D status of the host has an impact on bone mass and muscle function;
ascertain whether the vitamin D status of the host has an impact on the function of cells of the immune system;
determine the effects of correction of vitamin insufficiency on the musculoskeletal and immune systems.
All tests are designed to gauge the state of the circulating and urine factors that contribute to overall calcium balance and/or imbalance. This will include screening for the presence or absence of active and latent infection with the agent that causes TB. If evidence of active TB is identified, one of the physician investigators in this study will inform the subject of the outcome of the screening test and this information will be reported to the California State Health Department.
Additionally, blood and related medical information will ultimately be stored in our UCLA Repository (Human Vitamin D Sample Bank) in the CTRC (Clinical Translational Research Center) in order to allow sharing of the cells with other approved researchers. The cells may be used for other future research related to the purposes described above.
We will enroll vitamin D-deficient subjects (African American, Hispanic and white) and vitamin D-sufficient matching controls against which to compare them. Deficient subjects will be randomized to receive a total of 500,000 IU of vitamin D2 or D3, at the standard replacement dose of vitamin 50,000 IU twice weekly for 5 weeks. Subjects will complete screening medical history, questionnaire, biochemical and DXA (if indicated for low bone mineral density) screening, and exam of muscle strength and/or back curvature (if indicated). Blood and urine will be collected to gauge the state of the circulating and urine factors that contribute to the subjects' overall calcium balance and/or imbalance, and to test for TB. After 5 weeks of vitamin D treatment, subjects will return for repeat testings. Subjects who are still vitamin D-deficient will undergo an additional 5-week regimen. Subjects for whom changes in bone mineral density and/or muscle strength are outcome measures will return one year later for repeat testing.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitamin D Deficiency
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
300 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vitamin D2
Arm Type
Experimental
Arm Description
Total of 500,000 IU vitamin D2 (50,000 IU twice weekly for 5 weeks)
Arm Title
Vitamin D3
Arm Type
Experimental
Arm Description
Total of 500,000 IU vitamin D3 (50,000 IU twice weekly for 5 weeks)
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D2
Intervention Description
Ergocalciferol vitamin D2
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D3
Intervention Description
Cholecalciferol vitamin D2
Primary Outcome Measure Information:
Title
Change in serum 25D
Time Frame
5 weeks
Secondary Outcome Measure Information:
Title
Change in bone mineral density by biochemistry
Time Frame
5 weeks
Title
Change in muscle strength by exam
Time Frame
5 weeks
Title
Change in muscle strength by questionnaire
Time Frame
5 weeks
Title
Change in bone mineral density by DXA scan
Time Frame
5 weeks
Title
Change in fractional urinary calcium:creatinine excretion ratio
Time Frame
5 weeks
Title
Change in serum 1,25D
Time Frame
5 weeks
Title
Change in serum iPTH
Time Frame
5 weeks
Title
Change in serum bone biomarkers
Time Frame
5 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
25D levels <30 ng/ml (Vitamin D sufficient) OR <20 ng/ml (Vitamin D deficient)
At least 18 years of age
Exclusion Criteria:
Hypercalcemia
Hyperparathyroidism
Hyperthyroidism
Hypercalciuria
Renal disease
Intestinal malabsorption any disorder that places the subject at risk for developing hypercalcemia or hypercalciuria during standard vitamin D replacement therapy owing to the presence of underlying dysregulated vitamin D metabolism (e.g., sarcoidosis, TB, etc)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John S Adams, MD
Organizational Affiliation
University of California, Los Angeles
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCLA
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
27192696
Citation
Shieh A, Chun RF, Ma C, Witzel S, Meyer B, Rafison B, Swinkels L, Huijs T, Pepkowitz S, Holmquist B, Hewison M, Adams JS. Effects of High-Dose Vitamin D2 Versus D3 on Total and Free 25-Hydroxyvitamin D and Markers of Calcium Balance. J Clin Endocrinol Metab. 2016 Aug;101(8):3070-8. doi: 10.1210/jc.2016-1871. Epub 2016 May 18.
Results Reference
derived
Learn more about this trial
Effects of Vitamin D Insufficiency in Man
We'll reach out to this number within 24 hrs